<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02176252</url>
  </required_header>
  <id_info>
    <org_study_id>D5611C00005</org_study_id>
    <nct_id>NCT02176252</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of AZD1722 in Healthy Male and Female Japanese Subjects</brief_title>
  <official_title>A Phase I, Double-blind, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects in Healthy Male and Female Japanese Subjects After Single and Multiple Doses (Bid) of AZD1722</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ardelyx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ardelyx</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to evaluate the safety, tolerability, pharmacodynamics and
      pharmacokinetics of AZD1722 in healthy Japanese subjects at increasing doses given for 7 days
      in order to allow for including Japanese subjects in future global studies. A cohort of
      Caucasian subjects will be included in the study to evaluate cardiac effects, assessed by
      digital ECGs (dECG) recordings, also in Caucasian subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>up to 3 weeks</time_frame>
    <description>Measurement of safety laboratories, ECGs, vital signs, and physical exams</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pharmacodynamic activity</measure>
    <time_frame>up to one week</time_frame>
    <description>24-hour stool sodium and phosphorus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pharmacokinetics</measure>
    <time_frame>up to one week</time_frame>
    <description>plasma drug concentration to calculate AUC, if possible</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">83</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>AZD1722</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation from 5 mg to 90 mg BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD1722</intervention_name>
    <arm_group_label>AZD1722</arm_group_label>
    <other_name>RDX5791</other_name>
    <other_name>Tenapanor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>AZD1722</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy man or woman

          -  Body mass index between 18 and 29.9 kg/m2, inclusive

        Exclusion Criteria:

          -  Diagnosis or treatment of any clinically symptomatic biochemical or structural
             abnormality of the gastrointestinal (GI) tract

          -  Any surgery on the small intestine or colon, excluding appendectomy

          -  Clinical evidence of significant cardiovascular, respiratory, renal, hepatic,
             gastrointestinal, hematologic, metabolic, endocrine, neurologic, psychiatric disease,
             or any condition that may interfere with the subject successfully completing the trial
             or that would present a safety risk to the subject.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David P Rosenbaum, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Ardelyx, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>WCCT Global</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2013</study_first_submitted>
  <study_first_submitted_qc>June 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2014</study_first_posted>
  <last_update_submitted>June 26, 2014</last_update_submitted>
  <last_update_submitted_qc>June 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

